Compass Therapeutics reported a fourth-quarter 2025 net loss of US$15.72 million and a full-year 2025 net loss of US$66.49 million, while advancing multiple oncology programs including the Phase 2/3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results